Review| Volume 132, ISSUE 4, P408-412, April 2019

Download started.


Diabetes Care for Patients Experiencing Homelessness: Beyond Metformin and Sulfonylureas

Published:November 22, 2018DOI:


      On any given night in the United States, an estimated 553,742 people are homeless. Applying a broader definition of homelessness that includes unstably housed people, an estimated 1.5% of Americans experience homelessness in a given year. Rates of diabetes are increasing among individuals experiencing homelessness. The social, psychological, and physical challenges of homelessness not only contribute to the rate of diabetes, but also complicate management. Unstable housing, limited medical resources, food insecurity, and competing priorities are barriers to diabetes care among patients experiencing homelessness. Homeless patients with diabetes more frequently develop specific comorbidities that require special attention, such as cardiovascular disease, substance abuse, depression, and foot wounds. The Affordable Care Act gave states the option to expand Medicaid to those earning up to 138% of the federal poverty level. This addressed a gap in coverage for low-income individuals not eligible for Medicaid or employer-sponsored insurance. With increased insurance coverage, this has increased the variety of medications available to treat hyperglycemia from type 2 diabetes beyond metformin, sulfonylureas, and insulin. Several of the newer classes of medications have advantages for patients experiencing homelessness, but also have special considerations in this vulnerable patient population. This narrative review will provide a review of dipeptidyl peptidase-4 inhibitors, glucagon-like peptide agonists, sodium glucose cotransporter-2 inhibitors, and thiazolidinediones in individuals experiencing homelessness.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Henry M
        • Watt R
        • Rosenthal L
        • Shivji A
        The 2017 Annual Homeless Assessment Report to Congress.
        Department of Housing and Urban Development, Washington, DC2017
        • Tsai J
        Lifetime and 1-year prevalence of homelessness in the US population: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III.
        J Public Health (Oxf). 2018; 40: 65-74
        • Bernstein RS
        • Meurer LN
        • Plumb EJ
        • Jackson JL
        Diabetes and hypertension prevalence in homeless adults in the United States: a systematic review and meta-analysis.
        Am J Public Health. 2015; 105: e46-e60
        • White MC
        • Tulsky JP
        • Dawson C
        • Zolopa AR
        • Moss AR
        Association between time homeless and perceived health status among the homeless in San Francisco.
        J Community Health. 1997; 22: 271-282
        • Axon RN
        • Gebregziabher M
        • Dismuke CE
        • et al.
        Differential impact of homelessness on glycemic control in veterans with type 2 diabetes mellitus.
        J Gen Intern Med. 2016; 31: 1331-1337
        • Thornley S
        • Marshall R
        Lack of housing, hospital treatment and premature mortality: a cohort study of people in Counties Manukau district.
        N Z Med J. 2016; 129: 84-93
        • White BM
        • Logan A
        • Magwood GS
        Access to diabetes care for populations experiencing homelessness: an integrated review.
        Curr Diab Rep. 2016; 16: 112
        • DiPietro BY
        • Kindermann D
        • Schenkel SM
        Ill, itinerant, and insured: the top 20 users of emergency departments in Baltimore city.
        ScientificWorldJournal. 2012; 2012726568
        • Randall L
        • Begovic J
        • Hudson M
        • et al.
        Recurrent diabetic ketoacidosis in inner-city minority patients: behavioral, socioeconomic, and psychosocial factors.
        Diabetes Care. 2011; 34: 1891-1896
        • Dinour LM
        • Bergen D
        • Yeh MC
        The food insecurity-obesity paradox: a review of the literature and the role food stamps may play.
        J Am Diet Assoc. 2007; 107: 1952-1961
        • Bowen EA
        • Bowen SK
        • Barman-Adhikari A
        Prevalence and covariates of food insecurity among residents of single-room occupancy housing in Chicago, IL, USA.
        Public Health Nutr. 2016; 19: 1122-1130
        • O'Toole TP
        • Roberts CB
        • Johnson EE
        Screening for food insecurity in six veterans administration clinics for the homeless, June-December 2015.
        Prev Chronic Dis. 2017; 14: E04
        • Doom JR
        • Mason SM
        • Suglia SF
        • Clark CJ
        Pathways between childhood/adolescent adversity, adolescent socioeconomic status, and long-term cardiovascular disease risk in young adulthood.
        Soc Sci Med. 2017; 188: 166-175
        • Lee TC
        • Hanlon JG
        • Ben-David J
        • et al.
        Risk factors for cardiovascular disease in homeless adults.
        Circulation. 2005; 111: 2629-2635
        • Whicher C
        • Price HC
        • Holt RI
        Antipsychotic medication and type 2 diabetes and impaired glucose regulation.
        Eur J Endocrinol. 2018; 178: R245-R258
        • Gorczynski P
        • Patel H
        • Ganguli R
        Adherence to diabetes medication in individuals with schizophrenia: a systematic review of rates and determinants of adherence.
        Clin Schizophr Relat Psychoses. 2017; 10: 191-200
        • Barshes NR
        • Mindru C
        • Ashong C
        • Rodriguez-Barradas M
        • Trautner BW
        Treatment failure and leg amputation among patients with foot osteomyelitis.
        Int J Low Extrem Wounds. 2016; 15: 303-312
        • To MJ
        • Brothers TD
        • Van Zoost C
        Foot conditions among homeless persons: a systematic review.
        PLoS One. 2016; 11e0167463
        • DiPietro B
        Insurance coverage at health care for the homeless projects, 2013-2015.
        National Health Care for the Homeless Council, 2017 (Available at:)
        • Inzucchi SE
        • Bergenstal RM
        • Buse JB
        • et al.
        Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
        Diabetes Care. 2012; 35: 1364-1379
        • Amori RE
        • Lau J
        • Pittas AG
        Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
        JAMA. 2007; 298: 194-206
        • Davies M
        • Pieber TR
        • Hartoft-Nielsen ML
        • Hansen OKH
        • Jabbour S
        • Rosenstock J
        Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial.
        JAMA. 2017; 318: 1460-1470
        • Htike ZZ
        • Zaccardi F
        • Papamargaritis D
        • Webb DR
        • Khunti K
        • Davies MJ
        Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
        Diabetes Obes Metab. 2017; 19: 524-536
        • Aroda VR
        A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials.
        Diabetes Obes Metab. 2018; 20: 22-33
        • Singh S
        • Chang HY
        • Richards TM
        • Weiner JP
        • Clark JM
        • Segal JB
        Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
        JAMA Intern Med. 2013; 173: 534-539
        • Azoulay L
        • Filion KB
        • Platt RW
        • et al.
        Association between incretin-based drugs and the risk of acute pancreatitis.
        JAMA Intern Med. 2016; 176: 1464-1473
        • Li L
        • Shen J
        • Bala MM
        • et al.
        Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
        BMJ. 2014; 348: g2366
        • Monami M
        • Nreu B
        • Scatena A
        • et al.
        Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
        Diabetes Obes Metab. 2017; 19: 1233-1241
        • Marso SP
        • Daniels GH
        • Brown-Frandsen K
        • et al.
        Liraglutide and cardiovascular outcomes in type 2 diabetes.
        N Engl J Med. 2016; 375: 311-322
        • Marso SP
        • Bain SC
        • Consoli A
        • et al.
        Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.
        N Engl J Med. 2016; 375: 1834-1844
        • Bailey CJ
        • Gross JL
        • Pieters A
        • Bastien A
        • List JF
        Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
        Lancet. 2010; 375: 2223-2233
        • Bolinder J
        • Ljunggren O
        • Kullberg J
        • et al.
        Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
        J Clin Endocrinol Metab. 2012; 97: 1020-1031
        • Tikkanen I
        • Narko K
        • Zeller C
        • et al.
        Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
        Diabetes Care. 2015; 38: 420-428
        • Zinman B
        • Wanner C
        • Lachin JM
        • et al.
        Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
        N Engl J Med. 2015; 373: 2117-2128
        • Neal B
        • Perkovic V
        • Mahaffey KW
        • et al.
        Canagliflozin and cardiovascular and renal events in type 2 diabetes.
        N Engl J Med. 2017; 377: 644-657
        • Schwarzkopf R
        • Perretta DJ
        • Russell TA
        • Sheskier SC
        Foot and shoe size mismatch in three different New York City populations.
        J Foot Ankle Surg. 2011; 50: 391-394
        • Muirhead L
        • Roberson AJ
        • Secrest J
        Utilization of foot care services among homeless adults: implications for advanced practice nurses.
        J Am Acad Nurse Pract. 2011; 23: 209-215
        • Lehmann JM
        • Moore LB
        • Smith-Oliver TA
        • Wilkison WO
        • Willson TM
        • Kliewer SA
        An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).
        J Biol Chem. 1995; 270: 12953-12956
        • Aronoff S
        • Rosenblatt S
        • Braithwaite S
        • Egan JW
        • Mathisen AL
        • Schneider RL
        Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
        Diabetes Care. 2000; 23: 1605-1611
        • Rosenblatt S
        • Miskin B
        • Glazer NB
        • Prince MJ
        • Robertson KE
        • Pioglitazone 026 Study Group
        The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
        Coron Artery Dis. 2001; 12: 413-423
        • Goldberg RB
        • Kendall DM
        • Deeg MA
        • et al.
        A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
        Diabetes Care. 2005; 28: 1547-1554
        • Yki-Järvinen H
        N Engl J Med. 2004; 351: 1106-1118
        • Erdmann E
        • Dormandy JA
        • Charbonnel B
        • et al.
        The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
        J Am Coll Cardiol. 2007; 49: 1772-1780
        • Lincoff AM
        • Wolski K
        • Nicholls SJ
        • Nissen SE
        Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
        JAMA. 2007; 298: 1180-1188
        • Lewis JD
        • Ferrara A
        • Peng T
        • et al.
        Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.
        Diabetes Care. 2011; 34: 916-922